rethinkPeptides Search
Menu
Study breakdown

Exercise Boosts the Mitochondrial Peptide MOTS-c in Breast Cancer Survivors

Randomized Controlled Trial (Secondary Analysis)Moderate evidence
The takeaway

A 16-week exercise program increased levels of the mitochondrial peptide MOTS-c in non-Hispanic White breast cancer survivors, with higher MOTS-c linked to reduced body fat, insulin resistance, and inflammation.

p < 0.01

Post-exercise MOTS-c levels were significantly associated with reduced fat mass, body weight, insulin resistance, and inflammation in non-Hispanic White breast cancer survivors

What the researchers found

A 16-week aerobic and resistance exercise intervention significantly increased MOTS-c levels in non-Hispanic White breast cancer survivors, with post-exercise MOTS-c associated with reductions in fat mass, body weight, HOMA-IR, and CRP, and increased lean mass (p < 0.01).

Why it matters

This connects the benefits of exercise to a specific mitochondrial peptide, suggesting MOTS-c may partly explain how exercise protects cancer survivors from metabolic complications. Ethnic differences in response highlight the need for personalized approaches.

The numbers in context

25 Hispanic + 24 non-Hispanic White BCS; 16-week intervention; p < 0.01 for MOTS-c associations with fat mass, body weight, HOMA-IR, CRP, lean mass

How the study worked

Randomized controlled trial (secondary analysis). Stage I-III breast cancer survivors randomized to 16-week aerobic plus resistance exercise or standard care. Fasting plasma MOTS-c measured by in-house ELISA. Statistical analysis via paired t-test and repeated measures ANOVA.

Who was studied

Stage I-III Hispanic and non-Hispanic White breast cancer survivors

What this study cannot tell us

Secondary analysis with small sample size (49 total). MOTS-c response differed by ethnicity, possibly confounded by baseline metabolic differences. In-house ELISA used for MOTS-c measurement may limit reproducibility. Exercise intervention effects cannot be isolated to MOTS-c alone.

How to read the evidence

Moderate evidence: randomized controlled trial design but small sample size (49), secondary analysis, and in-house assay methodology.

When this study was published

Published in 2021. MOTS-c research has expanded significantly since, with growing interest in mitochondrial-derived peptides and exercise mimetics.

The bigger picture

MOTS-c is emerging as an important exercise-responsive mitochondrial peptide. Understanding how it mediates exercise benefits could lead to peptide-based therapies for patients who cannot exercise, and ethnic differences in MOTS-c response have implications for precision medicine.

Questions still open

  • Could MOTS-c supplementation replicate exercise benefits for cancer survivors who cannot exercise?
  • What specific mitochondrial DNA variations explain the different MOTS-c response between ethnic groups?
  • Does the exercise-induced MOTS-c increase persist after the exercise program ends?

Common questions

What is MOTS-c?
MOTS-c is a small peptide produced by mitochondria (the energy factories in cells). It acts as an exercise mimetic, meaning it can trigger some metabolic benefits similar to physical activity, including improved insulin sensitivity and reduced inflammation.
Why did Hispanic and non-Hispanic White survivors respond differently?
The researchers suspect ethnic-specific variations in mitochondrial DNA affect how much MOTS-c is produced in response to exercise. Hispanic participants also had different baseline metabolic profiles, which may have influenced the results.

Read the original research

Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.

Scientific reports, 11(1), 16916

Citation

Dieli-Conwright, Christina M; Sami, Nathalie; Norris, Mary K; Wan, Junxiang; Kumagai, Hiroshi; Kim, Su-Jeong; Cohen, Pinchas. (2021). Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.. Scientific reports, 11(1), 16916. https://doi.org/10.1038/s41598-021-96419-z